Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001312050 | SCV001502478 | pathogenic | not provided | 2020-10-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001312050 | SCV002211693 | pathogenic | not provided | 2024-11-15 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 25 of the VARS2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in VARS2 are known to be pathogenic (PMID: 29313548). This variant is present in population databases (rs200075594, gnomAD 0.03%). Disruption of this splice site has been observed in individual(s) with VARS2-related mitochondrial disease (PMID: 29314548). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 933237). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV001201411 | SCV002810746 | likely pathogenic | Combined oxidative phosphorylation defect type 20 | 2021-07-16 | criteria provided, single submitter | clinical testing | |
OMIM | RCV001201411 | SCV001372478 | pathogenic | Combined oxidative phosphorylation defect type 20 | 2020-07-10 | no assertion criteria provided | literature only |